RecruitingNot ApplicableNCT06965452

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy

Trans Arterial Embolization for Facet Arthropathy

Sponsor

Northwell Health

Enrollment

40 participants

Start Date

Aug 12, 2025

Study Type

INTERVENTIONAL

Conditions

Pain Osteoarthritis Facet Joint Arthropathy

Summary

This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Spinal angiography and embolization/ Embozene Microspheres for people with facet joint arthropathy, osteoarthritis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESpinal angiography and embolization/ Embozene Microspheres

Once consent is obtained the patient will be scheduled for spinal angiography and embolization. The patient will undergo the procedure at North Shore University Hospital. After embolization the patient will be monitored in recovery for 5 hours and then discharged to home. The primary objective of this study is to examine the safety and feasibility of trans arterial embolization of the facet joint using Embozene Microspheres for the treatment of back pain from facet arthropathy and osteoarthritis.